La Jolla Lupus Treatment LJP 394 Tradenames Could Include Luarc, Ipsilar
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
La Jolla Pharmaceutical may be considering Bentrela, Ipsilar, Luarc and Sprinza as names for its systemic lupus erythematosus (SLE) treatment LJP 394. The San Diego-based firm submitted the names to the Patent & Trademark Office for antibody-mediated diseases, including SLE.